THE 2-MINUTE RULE FOR MBL77

For patients with symptomatic illness demanding therapy, ibrutinib is commonly proposed based upon 4 section III randomized clinical trials evaluating ibrutinib with chlorambucil monotherapy106 and other normally utilized CIT combinations, specifically FCR, bendamustine as well as rituximab and chlorambucil moreover obinutuzumab (ClbO).107–109 Ib